Recursion Pharmaceuticals, Inc. Stock price
Equities
RXRX
US75629V1044
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.97 USD | -1.97% | -9.94% | +1.12% |
Mar. 15 | Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing | MT |
Mar. 11 | Recursion Pharmaceuticals to Open London Office | MT |
Financials (USD)
Sales 2024 * | 53.92M | Sales 2025 * | 60.67M | Capitalization | 2.39B |
---|---|---|---|---|---|
Net income 2024 * | -411M | Net income 2025 * | -481M | EV / Sales 2024 * | 38.4 x |
Net cash position 2024 * | 322M | Net cash position 2025 * | 279M | EV / Sales 2025 * | 34.8 x |
P/E ratio 2024 * |
-5.99
x | P/E ratio 2025 * |
-5.42
x | Employees | 500 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.39% |
1 day | -1.45% | ||
1 week | -8.13% | ||
Current month | -24.44% | ||
1 month | -34.47% | ||
3 months | -4.95% | ||
6 months | +30.72% | ||
Current year | +3.14% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 41 | 13-11-04 | |
Blake Borgeson
FOU | Founder | 42 | 13-11-04 |
Dean Li
FOU | Founder | 62 | 13-11-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 20-03-19 |
Chairman | 60 | 20-03-31 | |
Dean Li
FOU | Founder | 62 | 13-11-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.51% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 9.97 | -1.97% | 5 433 595 |
24-03-27 | 10.17 | -1.45% | 3,999,372 |
24-03-26 | 10.32 | -1.99% | 5,067,181 |
24-03-25 | 10.53 | +0.38% | 3,831,136 |
24-03-22 | 10.49 | -1.50% | 3,695,419 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.14% | 2.39B | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.45% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |